Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation therapy oncology group randomized clinical trial 9910

Journal of Clinical Oncology

Volumn 33, Issue 4, 2015, Pages 332-339

  Pisansky, Thomas M ^a   Hunt, Daniel ^b   Gomella, Leonard G ^c   Amin, Mahul B ^d   Balogh, Alexander G ^l   Chinn, Daniel M ^e   Seider, Michael J ^g   Duclos, Marie ^m   Rosenthal, Seth A ^f   Bauman, Glenn S ⁿ   Gore, Elizabeth M ^h   Rotman, Marvin Z ⁱ   Lukka, Himanshu R ^o   Shipley, William U ^j   Dignam, James J ^b,k   Sandler, Howard M ^d  

^a MAYO CLINIC   (United States)

^b Radiation Therapy Oncology Group Statistical Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e John Muir Medical Center   (United States)

^f Sutter Medical Center   (United States)

^g AKRON CITY HOSPITAL   (United States)

^h CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

^l TOM BAKER CANCER CENTRE   (Canada)

^m MCGILL UNIVERSITY   (Canada)

ⁿ London Regional Cancer Program   (United Kingdom)

^o MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GOSERELIN; LEUPRORELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; BLOOD; CANCER GRADING; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIOTHERAPY; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; TIME FACTORS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84921927316     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.0662     Document Type: Conference Paper

References (30)

1. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005
2. Roach M 3rd, Bae K, Speight J, et al: Shortterm neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008
3. Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497-2504, 2008
4. Jones CU, Hunt D, McGowan DG, et al: Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365:107-118, 2011
5. Lawton CA, DeSilvio M, Roach M 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007
6. Zietman AL, Nakfoor BM, Prince EA, et al: The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 3:31-36, 1997
7. Fleming ID, Cooper JS, Henson DE, et al: (eds): Prostate, in AJCC Cancer Staging Manual (ed 5). Philadelphia, PA, Lippincott-Raven Publishers, 1997, pp 219-224
8. Zelen M: The randomization and stratification of patients to clinical trials. J Chronic Dis 27:365-375, 1974
9. American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
10. Roach M 3rd, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
11. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
14. Lan KKG, Simon R, Halperin M: Stochastically curtailed tests in long-term clinical trials theory. Commun Stat Simul C 1:207-219, 1982
15. Green S, Benedetti J, Crowley J: Clinical Trials in Oncology. London, United Kingdom, Chapman and Hall/CRC, 2002
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
18. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
19. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
20. Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8:162-200, 2010
21. Ganz PA, Barry JM, Burke W, et al: National Institutes of Health State-of-the-Science Conference: Role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 156:591-595, 2012
22. Nguyen PL, Chen MH, Beard CJ, et al: Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 77:1046-1052, 2010
23. Denham JW, Steigler A, Lamb DS, et al: Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 12:451-459, 2011
24. D'Amico AV, Chen MH, Crook J, et al: Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol 29:4682-4687, 2011
25. Armstrong JG, Gillham CM, Dunne MT, et al: A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 81:35-45, 2011
26. Crook J, Ludgate C, Malone S, et al: Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 73:327-333, 2009
27. Dearnaley DP, Jovic G, Syndikus I, et al: Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15:464-473, 2014
28. Castle KO, Hoffman KE, Levy LB, et al: Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Int J Radiat Oncol Biol Phys 85:693-699, 2013
29. Rodrigues G, Lukka H, Warde P, et al: The prostate cancer risk stratification (ProCaRS) project: Recursive partitioning risk stratification analysis. Radiother Oncol 109:204-210, 2013
30. Zumsteg ZS, Spratt DE, Pei I, et al: A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64:895-902, 2013